A Pancreatic Cancer Breakthrough, and New Hope for an Off-the-Shelf CAR-T Treatment
Daraxonrasib nearly doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy, Revolution Medicines said.
7 Articles
7 Articles
Pancreatic cancer drug doubles median survival time
A new pancreatic cancer drug doubled median survival time, a significant, if imperfect, advance against a stubborn disease. While most cancers’ treatment has improved, pancreatic cancer remains intractable. Most patients die within months of diagnosis. Daraxonrasib boosted survival from six months to 13, meaningful against a disease where progress is usually measured in weeks. But it suggests that RAS-inhibitor drugs, which target mutations driv…
Daraxonrasib allows us to double the life expectancy of patients at an advanced stage of this particularly aggressive cancer. Two specialists share their enthusiasm.
Landmark Pancreatic Cancer Trial Highlights Promise of RAS-Targeting Daraxonrasib
Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma (PDAC). In the RASolute 302 trial, patients receiving daraxonrasib achieved longer progression‑free survival (PFS) and overall survival (OS) than those on standard cytotoxic chemotherapy. The RASolute 302 trial enrolled patients with pancreatic tumors…
_**The results of a clinical trial reveal a significant advance, with oral treatment that considerably prolongs the survival of patients.**_ An experimental treatment gives rise to a measured optimism in the management of cancer of the pancreas, a disease known for its severe prognosis. An American laboratory has recently released promising data from a trial [...] Read more A new therapeutic hope for cancer of the pancreas appeared first on Le S…
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
